- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00880932
Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert
April 13, 2009 updated by: University of Pennsylvania
The Effect of Customized Alerts Versus Generic Alerts for the Prescription of Warfarin and NSAID
The hypothesis is that a newly formatted electronic alert that requires the prescriber to pause and enter a specific "reason for override" on this alert, will cause prescribers in the intervention group to be significantly less likely to prescribe the combination of warfarin and NSAID than prescribers in the control group.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1865
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Phila, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- All resident physicians (RP) and nurse practitioners (NP) involved in inpatient care at two hospitals of the University of Pennsylvania
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: customized electronic alert
This intervention was not targeted to patients with a disease but to the providers.
The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a "reason for override" whenever the combination drugs of warfarin and NSAID were ordered together.
|
|
No Intervention: Standard practice
The control group was not patients but the providers.
Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Decreased rate of prescription of the combination of warfarin and NSAID
Time Frame: 17 months
|
17 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2006
Primary Completion (Actual)
December 1, 2007
Study Completion (Actual)
December 1, 2007
Study Registration Dates
First Submitted
April 13, 2009
First Submitted That Met QC Criteria
April 13, 2009
First Posted (Estimate)
April 14, 2009
Study Record Updates
Last Update Posted (Estimate)
April 14, 2009
Last Update Submitted That Met QC Criteria
April 13, 2009
Last Verified
April 1, 2009
More Information
Terms related to this study
Other Study ID Numbers
- 803787
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Warfarin and NSAID
-
University of North Carolina, Chapel HillCompleted
-
Oxford Pharmascience LtdCompletedNSAID Related Gastric IrritationUnited Kingdom
-
Dong-A ST Co., Ltd.CompletedNSAID-associated Gastroduodenal InjuryKorea, Republic of
-
Chinese University of Hong KongProfessor Bryan Ping Yen YAN (byan)Recruiting
-
University of AlbertaCompleted
-
University College CorkHoffmann-La Roche; Health Research Board, Ireland; ZyCare IncUnknown
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of S- and R-warfarin | Pharmacodynamics of WarfarinUnited States
-
Population Health Research InstituteCompleted
-
National University Hospital, SingaporeUnknownIndications for Warfarin TherapySingapore, Malaysia
-
Celal Bayar UniversityCompletedWarfarin Knowledge Level | International Normalized Ratio Control | Patient TrainingTurkey
Clinical Trials on Electronic Alert
-
Guangdong Provincial People's HospitalUnknownAcute Kidney Injury
-
Yale UniversityCompletedRisk EValuation And Its Impact on ClinicAL Decision Making and Outcomes in Heart Failure (REVeAL-HF)Heart FailureUnited States
-
Yale UniversityCompletedHigh Risk Atherosclerotic Cardiovascular DiseaseUnited States
-
Columbia UniversitySeattle Children's Hospital; New York Presbyterian Hospital; Agency for Healthcare...Completed
-
University of California, DavisCompleted
-
University Hospital Inselspital, BerneCompleted
-
University of Texas Southwestern Medical CenterActive, not recruitingHeart Failure | Diabetes Mellitus, Type 2United States
-
Brigham and Women's HospitalCompletedStroke | Atrial FibrillationUnited States